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Background: Recently, Abeliophyllum distichum Nakai (A. distichum) has been reported to exert the inhibitory effect
on angiotensin converting enzyme. However, no specific pharmacological effects from A. distichum have been
described. We performed in vitro study to evaluate anti-cancer properties of A. distichum and then elucidate the
potential mechanisms.
Methods: Cell viability was measured by MTT assay. ATF3 expression level was evaluated by Western blot or RT-PCR
and ATF3 transcriptional activity was determined using a dual-luciferase assay kit after the transfection of ATF3
promoter constructs. In addition, ATF3-dependent apoptosis was evaluated by Western blot after ATF3 knockdown
using ATF3 siRNA.
Results: Exposure of ethyl acetate fraction from the parts of A. distichum including flower, leaf and branch to human
colorectal cancer cells, breast cancer cells and hepatocellular carcinoma reduced the cell viability. The branch extracts
from A. distichum (EAFAD-B) increased the expression of activating transcription factor 3 (ATF3) and promoter activity,
indicating transcriptional activation of ATF3 gene by EAFAD-B. In addition, our data showed that EAFAD-B-responsible
sites might be between −147 and −85 region of the ATF3 promoter. EAFAD-B-induced ATF3 promoter activity was
significantly decreased when the CREB site was deleted. However, the deletion of Ftz sites did not affect ATF3 promoter
activity by EAFAD-B. We also observed that inhibition of p38MAPK and GSK3β attenuated EAFAD-B-mediated ATF3
promoter activation. Also, EAFAD-B contributes at least in part to increase of ATF3 accumulation.
Conclusion: These findings suggest that the anti-cancer activity of EAFAD-B may be a result of ATF3 promoter
activation and subsequent increase of ATF3 expression.
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Abeliophyllum distichum Nakai (A. distichum) has been
known to be a deciduous shrub and native to the south
and central areas of Korea [1]. Recently, A. distichum has
been reported to exert the inhibitory effect on angiotensin
converting enzyme [1]. However, no specific pharmaco-
logical effects from A. distichum have been described.
Therefore, extensive biological screenings of A. distichum
may be necessary to examine the potential use.
Activating transcription factor 3 (ATF3) as a member
of the ATF/CREB family is activated under various
physiological and pathological stimuli [2], which has
been regarded to exert cell-depending effects including
cell cycle arrest and apoptosis [3,4]. For the incidence
and development of cancer, the roles of ATF3 in cancer
progression and anti-cancer therapeutics are complex.
There are growing evidences to suggest that ATF3 is
expressed in cells treated with serum and growth factor
and induces DNA synthesis and expression of cyclin D1
in hepatocytes [5,6]. Furthermore, ATF3 activates the
canonical Wnt/β-catenin pathway in human breast cancer
cell [7]. However, ATF3 activation promotes a proapopto-
tic response, as there are evidences to suggest that ATF3
overexpression induced apoptosis in human colorectal
cancer cells [8-10]. Therefore, it is suggested that ATF3
activation may be a promising cancer preventive and
therapeutic target in human colorectal cancer.
In the course of this investigation, we tested the anti-
cancer effect of A. distichum in human cancer cell lines
and elucidated the potential anti-cancer mechanism of
A. distichum in human colorectal cancer cells.Methods
Chemicals
Cell culture media, Dulbecco's Modified Eagle medium
(DMEM)/F-12 1:1 Modified medium (DMEM/F-12) was
purchased from Lonza (Walkersville, MD, USA). 3-(4,5-
dimethylthizaol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) were purchased from Sigma Aldrich (St. Louis,
MO, USA). SB203580, PD98059 were purchased from
Calbiochem (San Diego, CA, USA). SB216763 were pur-
chased from Sigma Aldrich. ATF3 antibody and ATF3
siRNA were purchased from Santa Cruz Biotechnology,
Inc (Santa Cruz, CA, USA). Antibodies against β-actin,
Poly (ADP-ribose) polymerase (PARP), p38, p-p38, ERK1/
2, p-ERK1/2, p-GKS3β and GKS3β were purchased
from Cell Signaling (Bervely, MA, USA). ATF3 promoter
constructs (−1420/+34, −718/+34, −514/+34, −318/+34,
−147/+34 and −84/+34, pATF3-514 del Ftz and pATF3-
514 del CRE) were kindly provided by Dr. S-H Lee
(University of Maryland College Park, Maryland, USA).
All chemicals were purchased from Fisher Scientific,
unless otherwise specified.Sample preparation
The plant parts of A. distichum (voucher number: Park
1001(ANH)) was formally identified by Jae Ho Park as
the professor of Jungwon University, Korea. Its flower, leaf
and branch were cultivated and collected at Goesan-gun,
Chungbuk, Korea. Five hundred grams of fresh parts was
extracted with 1,000 ml of 80% methanol with shaking
for 24 h. The methanol-soluble fraction was filtered
and concentrated to approximately 20 ml volume using
a vacuum evaporator and a fraction was placed in a
separating funnel. The ethyl acetate fractions from the
parts of A. distichum was separated from the mixture,
evaporated by a vacuum evaporator and prepared aseptic-
ally and kept in a refrigerator until use.Cell culture and treatment
Human colorectal cancer cell lines (HCT116, SW480 and
LoVo cells), human breast cancer cell lines (MCF-7 and
MDA-MB-231), hepatocellular carcinoma cells (HepG-2)
and colon normal cells (CCD-18co) were purchased Korean
Cell Line Bank (Seoul, Korea) and grown in DMEM/F-12
supplemented with 10% fetal bovine serum (FBS), 100 U/
ml penicillin and 100 μg/ml streptomycin. The cells were
maintained at 37°C under a humidified atmosphere of
5% CO2. Ethyl acetate fractions from A. distichum were
dissolved in dimethyl sulfoxide (DMSO) and treated to
cells. DMSO was used as a vehicle and the final DMSO
concentration was not exceeded 0.1% (v/v).Cell viability
Cell viability was measured using MTT assay system.
Briefly, cells were plated onto 96-well plated and grown
overnight. The cells were treated with 0, 50, 100 and
200 μg/ml of EAFAD-B for 24 and 48 h. Then, the cells
were incubated with 50 μl of MTT solution (1 mg/ml) for
the additional 2 h. The resulting crystals were dissolved
in DMSO. The formation of formazan was measured by
reading absorbance at a wavelength of 570 nm.Reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA was prepared using a RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) and total RNA (1 μg) was reverse-
transcribed using a Verso cDNA Kit (Thermo Scientific,
Pittsburgh, PA, USA) according to the manufacturer’s
protocol for cDNA synthesis. PCR was carried out using
PCR Master Mix Kit (Promega, Madison, WI, USA) with
primers for human ATF3 and human GAPDH as follows:
human ATF3: 5′-gtttgaggattttgctaacctgac-3′, and reverse
5′-agctgcaatcttatttctttctcgt-3′; huaman GAPDH: forward
5’-acccagaagactgtggatgg-3’ and reverse 5’-ttctagacggcaggt
caggt-3’.
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Transient transfections were performed using the Poly-
Jet DNA transfection reagent (SignaGen Laboratories,
Ijamsville, MD, USA) according to the manufacturers’
instruction. HCT116 and SW480 cells were plated in
12-well plates at a concentration of 2 × 105 cells/well.
After growth overnight, plasmid mixtures containing
0.5 μg of ATF3 promoter linked to luciferase and
0.05 μg of pRL-null vector were transfected for 24 h.
The transfected cells were cultured in the absence or
presence of the ethyl acetate fractions for the indicated
times. The cells were then harvested in 1 × luciferase
lysis buffer, and luciferase activity was normalized to
the pRL-null luciferase activity using a dual-luciferase
assay kit (Promega).Transfection of small interference RNA (siRNA)
The cells were plated in six-well plates and incubated
overnight. HCT116 cells were transfected with control
siRNA and ATF3 siRNA for 48 h at a concentration of
100 nM using TransIT-TKO transfection reagent (Mirus,
Madison, WI) according to the manufacturer's instruction.
Then the cells were treated with EAFAD-B (200 μg/ml)
for 24 h.SDS-PAGE and Western blot
After EAFAD-B treatment, cells were washed with 1 ×
phosphate-buffered saline (PBS), and lysed in radioimmu-
noprecipitation assay (RIPA) buffer (Boston Bio Products,
Ashland, MA, USA) supplemented with protease inhibitor
cocktail (Sigma Aldrich) and phosphatase inhibitor cock-
tail (Sigma Aldrich), and centrifuged at 15,000 × g for
10 min at 4°C. Protein concentration was determined
by the bicinchoninic acid (BCA) protein assay (Pierce,
Rockford, IL, USA). The proteins were separated on SDS-
PAGE and transferred to PVDF membrane (Bio-Rad
Laboratories, Inc., Hercules, CA, USA). The membranes
were blocked for non-specific binding with 5% nonfat dry
milk in Tris-buffered saline containing 0.05% Tween 20
(TBS-T) for 1 h at room temperature and then incubated
with specific primary antibodies in 5% nonfat dry milk
at 4°C overnight. After three washes with TBS-T, the
blots were incubated with horse radish peroxidase (HRP)-
conjugated immunoglobulin G (IgG) for 1 h at room
temperature and chemiluminescence was detected with
ECL Western blotting substrate (Amersham Biosciences)
and visualized in Polaroid film.Statistical analysis
Statistical analysis was performed with the Student's
unpaired t-test, with statistical significance set at *,
P < 0.05.Results
A. distichum induces reduction of cell viability against
various cancer cells
The effects of the ethyl acetate fraction from the parts of
A. distichum on cell viability were evaluated in human
breast cancer cells (MCF-7 and MDA-MB-231), colorectal
cancer cells (HCT116 and SW480), hepatocellular carcin-
oma cells (HepG-2) and colon normal cells (CCD-18co)
by MTT assay. As shown in Figure 1A, cell viability of all
cancer cells was reduced by the treatment of 100 μg of the
ethyl acetate fraction from the parts of A. distichum for
24 h and this effect was highest in the ethyl acetate frac-
tion from the branch of A. distichum. There, we collected
the ethyl acetate fraction from the branch of A. distichum
(EAFAD-B) for the further studies elucidating the poten-
tial mechanism by which A. distichum exerts anti-cancer
activity. In a dose-experiment for evaluating the effect of
EAFAD-B on cell viability, EAFAD-B dose-dependently
reduced the cell viability of human colorectal cancer
cells (Figure 1B). However, EAFAD-B induced minimal
reduction of cell viability in CCD-18co (colon normal
cells) (Figure 1C). These data indicate that EAFAD-B’s
anti-cancer activity may be cancer-specific.
Effect of EAFAD-B on ATF3 expression and ATF3-
mediated apoptosis in human colorectal cancer cells
There is a growing body of evidence that ATF3 expression
could induce apoptosis in human colorectal cancer cells.
To test whether EAFAD-B affects ATF3 expression, we
measured ATF3 expression in HCT116 and SW480 cells
by Western blot and RT-PCR. As shown in Figure 2A and
B, ATF3 expression was activated in EAFAD-B-treated
HCT116 and SW480 cells. In addition, to elucidate a
molecular mechanism by which EAFAD-B increases
ATF3 expression in HCT116 and SW480 cells, we first
measured the mRNA level of ATF3 to determine whether
increase in ATF3 protein expression is involved in tran-
scriptional regulation. ATF3 mRNA was increased in
HCT116 and SW480 cells treated with EAFAD-B at the
dose-dependent manner (Figure 2C and D), which was
similar to protein expression. In addition, we confirmed
the transcriptional regulation of ATF3 gene by EAFAD-B
using ATF3 promoter luciferase constructs (pATF3-
1420/+34). As shown in Figure 2E and F, EAFAD-B
dose-dependently increased ATF3 promoter activity in
HCT116 and SW480 cells. In time-course experiment,
ATF3 promoter activity was increased at 3 h after EAFAD-
B treatment in both HCT116 and SW480 cells (Figure 2G
and H), while, ATF3 protein expression was slightly
induced at 1 h after EAFAD-B treatment (Figure 2I and J).
To see whether ATF3 expression is associated with
EAFAD-B-mediated apoptosis, cleaved PARP was mea-
sured by Western blot in ATF3 knock downed-HCT116
cells. As shown in Figure 2K, knockdown of ATF3 by
Figure 1 Effect of EAFAD on cell viability in a variety of cancer cells and normal colon cells. (A,B) Human colorectal cancer cells (HCT116
and SW480), breast cancer cells (MCF-7 and MDA-MB-231), hepatocellular carcinoma cells (HepG-2) and (C) normal colon cells (CCD-18co) were
plated overnight and then each fraction was treated for 24 h. Cell viability was measured using MTT assay as described in Materials and methods.
*P < 0.05 compared to cells without EAFAD treatment.
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that ATF3 may be one of important genes in apoptosis
by EAFAD-B.
Involvement of CREB in EAFAD-B-induced ATF3 activation
To elucidate a specific site of ATF3 promoter region
associated with promoter activation by EAFAD-B, ATF3
promoter luciferase constructs (pATF3-1420/+34, pATF3-
718/+34, pATF3-514/+34, pATF3-318/+34, pATF3-
147/+34 and pATF3-84/+34) were transfected into
HCT116 and SW480 cells and treated with 200 μg/ml
of EAFAD-B for 24 h. As shown in Figure 3A and B,
the fold inductions in HCT116 were 5.2, 5.0, 3.9, 4.1,
3.9 and 2.1 in pATF3-1420/+34, pATF3-718/+34, pATF3-
514/+34, pATF3-318/+34, pATF3-147/+34 and pATF3-
84/+34, respectively. In SW480 cells, EAFAD-B activated
ATF3 promoter activity by 7.5, 7.4, 5.7, 5.4, 3.8 and 2.5
in pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34,
pATF3-318/+34, pATF3-147/+34 and pATF3-84/+34,
respectively. EAFAD-B increased ATF3 promoter activity
by 4-fold using ATF3 promoter construct containing
regions between −1420 and −147, while EAFAD-B slightly
increased ATF3 promoter activity using a construct
containing the −84/+34 region, which indicates thatATF3 promoter region (−146/-85) may be important for
ATF3 activation by EAFAD-B. The Fushi tarazu (Ftz) and
CREB have been reported to be cis-acting elements in
ATF3 promoter containing −147 and −85 [9]. To identify
the role of each cis-acting element, each site-deleted ATF3
promoter constructs were transfected into HCT116 and
SW480 cells and and treated with 200 μg/ml of EAFAD-B
for 24 h. As shown in Figure 3C, EAFAD-B-induced ATF3
promoter activity was significantly decreased when the
CREB site was deleted. However, the deletion of Ftz sites
did not affect ATF3 promoter activity by EAFAD-B. These
data indicated that CREB is an important region in
EAFAD-B induced ATF3 expression.
ATF3 transcriptional activation by EAFAD-B is dependent
on p38 MAPK and GSK3β
To determine the upstream kinase affecting EAFAD-B-
induced ATF3 transcriptional activation, ATF3 promoter
construct (pATF3-1420/+34) was transfected into HCT116
and SW480 cells and then these cells were pretreated with
20 μM of PD98059 (ERK1/2 inhibitor), SB203580 (p38
inhibitor) or SB216763 (GSK3β) for 2 h and subsequently
co-treated with 200 μg/ml of EAFAD-B for 24 h. As shown
in Figure 4A and B, inhibitions of p38 MAPK by SB203580
Figure 2 Effect of EAFAD-B on ATF3 expression and ATF3-mediated apoptosis in human colorectal cancer cells. (A, B, I, J) HCT116 and
SW480 cells were plated and then treated with EAFAD-B. Cell lysates were subjected to SDS-PAGE the Western blot was performed using antibodies
against ATF3. Actin was used as internal control. (C, D) RT-PCR analysis of ATF3 gene expression, total RNA was prepared after EAFAD-B treatment for
24 h. GAPDH was used as internal control (E, F, G, H) For ATF3 promoter activity, luciferase construct containing −1420 to +34 of human ATF3 promoter
region was cotransfected with pRL-null vector and the cells were treated with EAFAD-B and luciferase activity was measured. *P < 0.05 compared to cells
without EAFAD-B treatment. (K) ATF3 siRNA was transfected into HCT116 for 48 h and then EAFAD-B was treated for 24 h. Cell lysates were subjected to
SDS-PAGE the Western blot was performed using antibodies against PARP. Actin was used as internal control.
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ATF3 transcriptional activation. However, inhibition of
ERK1/2 by PD98059 did not affect ATF3 activation by
EAFAD-B. We also tested that the inhibitions of
p38MAPK and GSK3β affect ATF3 protein level. In
these experiments, the inhibition of GSK3β by SB216763
inhibited the increase of ATF3 protein level by EAFAD-B,
while p38 MAPK inhibition did not affect ATF3 pro-
tein level in HCT116 cells (Figure 4C). However, the
inhibitions of p38MAPK and GSK3β reduced EAFAD-
B-induced ATF3 protein expression in SW480 cells
(Figure 4D). To see whether EAFAD-B affects the acti-
vation of p38, ERK1/2 and GSK3β, we measured the
phosphorylation level of these kinases by Western blot
and found that EAFAD-B increased the phosphorylation
of three kinases from 1 h after the treatment (Figure 4E).Interestingly, our findings indicate that inhibition of p38
MAPK differently affect ATF3 transcriptional activation
and increase of ATF3 protein in HCT116 cells. Moreover,
the time point to increase ATF3 protein level (1 h after
EAFAD-B treatment) is earlier than that to start ATF3
transcriptional activation (3 h after EAFAD-B treatment)
(Figure 2G-J). Thus, we hypothesize that EAFAD-B-
induced increase of ATF3 protein could be consequence
of ATF3 accumulation. To address this question, we
investigated the effect of EAFAD-B on ATF3 stability in
HCT116 cells. As shown in Figure 4F, the treatment of
cycloheximide (CHX) after pre-stimulation of EAFAD-B for
12 h decreased ATF3 protein level. However, co-treatment
of EAFAD-B with CHX attenuated CHX-induced decrease
of ATF3 protein level. In conclusion, these results demon-
strate that EAFAD-B increased the transcription activation
Figure 3 Identification of ATF3 promoter sites responsible for EAFAD-B-induced ATF3 activation. (A, B) Each indicated constructs or
(C, D) each deletion construct (0.5 μg) of the ATF3 promoter (0.5 μg) was co-transfected with 0.05 μg of pRL-null vector into HCT116 and SW480 cells,
and cells were treated with 200 μg/ml of EAFAD-B. Luciferase activity was measured. *P < 0.05 compared to cells without EAFAD-B treatment.
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activation and also EAFAD-B contributes at least in part to
increase of ATF3 accumulation.
Discussion
Cancer chemoprevention has received attention as the
most effective approach to reduce colorectal cancer related
mortality. Abeliophyllum distichum Nakai (A. distichum)
has been known to be a deciduous shrub and native to thesouth and central areas of Korea [1]. Recently, A. distichum
has been reported to exert the inhibitory effect on angioten-
sin converting enzyme [1]. However, no specific pharmaco-
logical effects from A. distichum have been described. In
search for approaches to augment the potential therapeutic
efficacy of A. distichum for human colorectal cancer, we
investigated the anticancer activity of A. distichum and the
role of ATF3 in apoptosis by A. distichum in human colo-
rectal cancer cells. In this study, we for the first time
Figure 4 Up-stream signaling pathways affecting EAFAD-B-mediated ATF3 activation. (A, B) Luciferase construct containing −1420 to +34
of human ATF3 promoter region was cotransfected with pRL-null vector. Then, the cells were pretreated with 20 μM of PD98059 (ERK1/2 inhibitor),
SB203580 (p38 inhibitor) or SB216763 (GSK3β inhibitor) and then co-treated with 200 μg/ml of EAFAD-B for 24 h. Luciferase activity was measured.
*P < 0.05 compared to cells without EAFAD-B treatment. (C, D) HCT116 and SW480 cells were pre-treated with 20 μM of PD98059 (ERK1/2 inhibitor),
SB203580 (p38 inhibitor) or SB216763 (GSK3β inhibitor) and then co-treated with 200 μg/ml of EAFAD-B for 24 h. Cell lysates were subjected to
SDS-PAGE the Western blot was performed using antibodies against ATF3. Actin was used as internal control. (E) SW480 cells were treated with
200 μg/ml of EAFAD-B for indicated times. Cell lysates were subjected to SDS-PAGE and the Western blot was performed using antibodies against
p-p38, p38, p-ERK1/2, ERK1/2, p-GSK3β or GSK3β. (F) HCT116 cells were pre-treated with 200 μg/ml of EAFAD-B for 12 h and then co-treated with
CHX (10 μg/ml) for the indicated times in absence/presence of EFAD-B. Cell lysates were subjected to SDS-PAGE and the Western blot was performed
using antibodies against ATF3. Actin was used as internal control.
Park et al. BMC Complementary and Alternative Medicine 2014, 14:487 Page 7 of 9
http://www.biomedcentral.com/1472-6882/14/487provide evidence that A. distichum exerts anti-cancer effect,
which especially is associated with ATF3 activation in
human colorectal cancer cells.
The activation of activating transcription factor 3 (ATF3)
has been known to exert a proapoptotic effect in human
colorectal cancer [8-10] and ATF3 is a major target of
some anticancer drugs including cisplatin [11] and
bortezomib [12]. In addition, there is a growing body of
evidences to suggest that antitumorigenic phytochemicals
induce ATF3-mediated apoptosis [13-15]. This indicates
that ATF3 may be an important molecular target of cancer
chemoprevention against human colorectal cancer. Our
data show that the ethyl acetate fraction from the branch
of A. distichum (EAFAD-B) increased ATF3 expression
and ATF3 knockdown by siRNA attenuated apoptosis by
EAFAD-B, which indicates that ATF3 may be one of the
molecular targets for anti-cancer activity of EAFAD-B in
human colorectal cancer cells.
ATF3 is both tumor suppressive in early stage tumori-
genesis and oncogenic in late stage tumorigenesis in
breast cancer cell lines [16]. Although ATF3 has been
well known to promote metastasis in the breast cancer[17], ATF3 expression can induce apoptosis in human
breast cancer cells (MCF-7 and MDA-MB-231) [18,19].
In addition, ATF3 has been reported to mediate the
suppression of cell viability in human hepatocellular
carcinoma cells (HepG-2) [20]. In this study, EAFAD-B
reduced the cell viability in MCF-7, MDA-MB-231 and
HepG-2 cells. Thus, the further elucidation of mechanisms
for ATF3 role involved in EAFAD-B-induced apoptosis
may be needed in human breast cancer and hepatocellular
carcinoma cells.
The level of ATF3 can be regulated by multiple mech-
anisms. One is through transcriptional regulation. In this
study, our data shows that EAFAD-B activated the
expression of ATF3 mRNA through increasing promoter
activity, which indicates upregulation of ATF3 by EAFAD-
B may be dependent on transcription. Another mechanism
to regulating ATF3 level is through suppression of protea-
somal degradation although it is generally believed that
ATF3 induction is activated mainly through transcriptional
regulation [21]. There is growing evidence that MDM2
induces ubiquitination and subsequent proteasomal deg-
radation of ATF3 [22]. In this study, we found two
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One is that EAFAD-B increased the protein level of
ATF3 at earlier time than mRNA level. Another evidence
is that p38 inhibition attenuated ATF3 promoter activation
by EAFAD-B, while did not affect ATF3 protein level. Fur-
thermore, we found that CHX treatment time-dependently
decreased ATF3 protein level upregulated by the pre-
treatment of EAFAD-B, while co-treatment of CHX
and EAFAD-B attenuated the reduction of ATF3 protein.
These findings indicate that EAFAD-B may inhibit ATF3
proteasomal degradation.
Many transcription factors such as NF-κB, EGR-1,
E2F, AP-1, CREB and Ftz have been identified to regu-
late ATF3 transcriptional activity [23]. We determined
that EAFAD-B-responsible sites for ATF3 transcrip-
tional activity might be between the −147 and −85 re-
gion in ATF3 promoter because ATF3 promoter activity
by EAFAD-B was more decreased in transfection of
ATF3 promoter (−85/+34) than other transfection such
as pATF3-1420/+34, pATF3-718/+34, pATF3-514/+34,
pATF3-318/+34, pATF3-147/+34. Especially, CREB and
Ftz are cis-acting elements in ATF3 promoter (−147/-85)
[9]. To identify the role of each cis-acting element affect-
ing EAFAD-B-mediated ATF3 transcriptional activa-
tion, each site-deleted ATF3 promoter constructs were
transfected into HCT116 and SW480 cells and we
found that EAFAD-B-induced ATF3 promoter activity
was significantly decreased when the CREB site was de-
leted. These data indicated that CREB is an important
region in EAFAD-B-induced ATF3 expression. However,
we do not exclude the effects of other transcription factors
because EAFAD-B-mediated ATF3 promoter activity was
gradually decreased in pATF3-1420/+34, pATF3-718/+34,
pATF3-514/+34, pATF3-318/+34, pATF3-147/+34 and
pATF3-84/+34. Thus, the further experiments for more
investigation of the transcription factors associated with
EAFAD-B-induced ATF3 activation may be needed. We
also observed the basal activity of ATF3 promoter was
different in ATF3 promoter constructs. We think that
ATF3 promoter activity can be affected by other transcrip-
tional activity such as Sp3, NF-kB and c-Jun. Indeed, Sp3
and c-Jun have been reported to increase basal ATF3
promoter activity [9,24].
It has been reported that ATF3 expression is regulated
by MAPK signaling [15,25] and GSK3β [14]. So, we
examined whether EAFAD-B-mediated ATF3 activation
is associated with the activation of ERK1/2, p38 or
GSK3β and found that EAFAD-B induced the phosphor-
ylation of ERK1/2, p38 or GSK3β and inhibition of p38
or GSK3β attenuated ATF3 promoter activity by EAFAD-B
in HCT116 and SW480 cells. However, ERK1/2 inhibition
did not affect ATF3 promoter activity. These findings indi-
cate that ATF3 activation by EAFAD-B may be dependent
on p38 or GSK3β but not ERK1/2. However, we do notexcluded that the EAFAD-B-induced ATF3 activation may
be overcome by ERK1/2 inhibitor.
Conclusions
These findings highlight that EAFAD-B increased the
transcription activation and increase of ATF3 protein level
through p38 and GSK3β activation and also EAFAD-B con-
tributes at least in part to increase of ATF3 accumulation.
In conclusion, the current study provides information on
the anti-cancer activity and the potential molecular mech-
anism of A. distichum.
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